New hope for Hard-to-Treat cancers: first human trial of VIR-5525 begins

NCT ID NCT06960395

Recruiting now Disease control Sponsor: Vir Biotechnology, Inc. Source: ClinicalTrials.gov ↗

First seen Mar 26, 2026 · Last updated May 26, 2026 · Updated 9 times

Summary

This early-phase study tests a new drug called VIR-5525, alone or with an immunotherapy (pembrolizumab), in adults with advanced solid tumors that have a protein called EGFR. The main goals are to check safety and find the right dose. Up to 450 participants will be enrolled across four parts of the study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Honor Health Research Institute
RECRUITING

Scottsdale, Arizona, 85258-4566, United States
MD Anderson
RECRUITING

Houston, Texas, 77030, United States
Princess Alexandra Hospital
RECRUITING

Woolloongabba, Queensland, 4102, Australia
Wollongong Hospital
RECRUITING

Wollongong, New South Wales, 2500, Australia

Conditions

Explore the condition pages connected to this study.

EGFR EGFR EGFR POSITIVE SOLID TUMORS SOLID TUMOR MALIGNANCIES